Current status of transcatheter mitral valve replacement_West China Medical Journal

Authors：

HE Jingjing , CHEN Fei , FENG Yuan ,  CHEN Mao

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

CHEN Mao, Email: hmaochen@vip.sina.com

Keywords：

Mitral regurgitation; transcatheter replacement; research update

DOI：

10.7507/1002-0179.202207157

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Mitral regurgitation is the most prevalent valvular heart disease, with a poor prognosis that brings a heavy burden to population health and socio-economics. Transcatheter repair is a relatively mature technique for mitral regurgitation, but is strict in anatomical screening and the reduction of regurgitation is limited. With the advance in techniques and technology, transcatheter replacement has become an attractive treatment modality for mitral regurgitation in succession to transcatheter repair. At present, several replacement devices have initiated clinical trials to establish feasibility. Early data has shown that transcatheter replacement for mitral regurgitation is safe and effective, which needs to be confirmed with larger population and longer follow-up. Besides, some technical challenges remain to be addressed, in order to increase accessibility of this innovative technology.

Citation： HE Jingjing, CHEN Fei, FENG Yuan, CHEN Mao. Current status of transcatheter mitral valve replacement. West China Medical Journal, 2022, 37(9): 1281-1287. doi: 10.7507/1002-0179.202207157 Copy

1.	Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
2.	Davidson LJ, Davidson CJ. Transcatheter treatment of valvular heart disease: a review. JAMA, 2021, 325(24): 2480-2494.
3.	Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e35-e71.
4.	Muller DWM, Farivar RS, Jansz P, et al. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol, 2017, 69(4): 381-391.
5.	Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
6.	Meredith I, Bapat V, Morriss J, et al. Intrepid transcatheter mitral valve replacement system: technical and product description. EuroIntervention, 2016, 12(Y): Y78-Y80.
7.	Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
8.	Cheung A, Webb J, Verheye S, et al. Short-term results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol, 2014, 64(17): 1814-1819.
9.	Barbanti M, Piazza N, Mangiafico S, et al. Transcatheter mitral valve implantation using the HighLife system. JACC Cardiovasc Interv, 2017, 10(16): 1662-1670.
10.	Maisano F, Benetis R, Rumbinaite E, et al. 2-year follow-up after transseptal transcatheter mitral valve replacement with the cardiovalve. JACC Cardiovasc Interv, 2020, 13(17): e163-e164.
11.	Alperi A, Del Val D, Ferreira-Neto AN, et al. Device profile of the AltaValve system for transcatheter mitral valve replacement: overview of its safety and efficacy. Expert Rev Med Devices, 2020, 17(7): 627-636.
12.	Nunes Ferreira-Neto A, Dagenais F, Bernier M, et al. Transcatheter mitral valve replacement with a new supra-annular valve: first-in-human experience with the AltaValve system. JACC Cardiovasc Interv, 2019, 12(2): 208-209.
13.	Goel SS, Zuck V, Christy J, et al. Transcatheter mitral valve therapy with novel Supra-Annular AltaValve: first experience in the United States. JACC Case Rep, 2019, 1(5): 761-764.
14.	Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol, 2014, 64(21): 2235-2243.
15.	Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. J Am Coll Cardiol, 2019, 73(11): 1239-1246.
16.	Whisenant B. TCT 8: Updated 30-day outcomes for the U. S. early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. (2019-09-28)[2022-09-08]. https://www.tctmd.com/slide/tct-8-updated-30-day-outcomes-us-early-feasibility-study-sapien-m3-transcatheter-mitral-valve.
17.	Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv, 2020, 13(20): 2418-2426.
18.	Modine T, Vahl TP, Khalique OK, et al. First-in-human implant of the cephea transseptal mitral valve replacement system. Circ Cardiovasc Interv, 2019, 12(9): e008003.
19.	Iung B, Delgado V, Lazure P, et al. Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. Eur Heart J, 2018, 39(15): 1295-1303.
20.	Gammie JS, Chikwe J, Badhwar V, et al. Isolated mitral valve surgery: the Society of Thoracic Surgeons Adult Cardiac Surgery Database analysis. Ann Thorac Surg, 2018, 106(3): 716-727.
21.	Urena M, Vahanian A, Brochet E, et al. Current indications for transcatheter mitral valve replacement using transcatheter aortic valves: valve-in-valve, valve-in-ring, and valve-in-mitral annulus calcification. Circulation, 2021, 143(2): 178-196.
22.	Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
23.	Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an 8-year single-center experience. JACC Cardiovasc Interv, 2015, 8(13): 1735-1744.
24.	D’Onofrio A, Tarja E, Besola L, et al. Early and midterm clinical and hemodynamic outcomes of transcatheter valve-in-valve implantation: results from a multicenter experience. Ann Thorac Surg, 2016, 102(6): 1966-1973.
25.	Eleid MF, Whisenant BK, Cabalka AK, et al. Early outcomes of percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc Interv, 2017, 10(19): 1932-1942.
26.	Murzi M, Berti S, Gasbarri T, et al. Transapical transcatheter mitral valve-in-valve implantation versus minimally invasive surgery for failed mitral bioprostheses. Interact Cardiovasc Thorac Surg, 2017, 25(1): 57-61.
27.	Kamioka N, Babaliaros V, Morse MA, et al. Comparison of clinical and echocardiographic outcomes after surgical redo mitral valve replacement and transcatheter mitral valve-in-valve therapy. JACC Cardiovasc Interv, 2018, 11(12): 1131-1138.
28.	Urena M, Brochet E, Lecomte M, et al. Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience. Eur Heart J, 2018, 39(28): 2679-2689.
29.	Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J, 2019, 40(5): 441-451.
30.	da Costa LPN, Palma JH, Barbosa Ribeiro H, et al. Transcatheter mitral valve-in-valve implantation: reports of the first 50 cases from a Latin American Centre. Interact Cardiovasc Thorac Surg, 2020, 30(2): 229-235.
31.	Guerrero M, Vemulapalli S, Xiang Q, et al. Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the united states: data from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv, 2020, 13(3): e008425.
32.	Guerrero M, Urena M, Himbert D, et al. 1-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Am Coll Cardiol, 2018, 71(17): 1841-1853.
33.	Praz F, Khalique OK, Lee R, et al. Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification. J Thorac Cardiovasc Surg, 2018, 156(1): 132-142.
34.	Alperi A, Granada JF, Bernier M, et al. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol, 2021, 77(24): 3058-3078.
35.	Gössl M, Thourani V, Babaliaros V, et al. Early outcomes of transcatheter mitral valve replacement with the Tendyne system in severe mitral annular calcification. EuroIntervention, 2022, 17(18): 1523-1531.
36.	Hensey M, Brown RA, Lal S, et al. Transcatheter mitral valve replacement: an update on current techniques, technologies, and future directions. JACC Cardiovasc Interv, 2021, 14(5): 489-500.
37.	Nakashima M, Williams M, He Y, et al. Multiphase assessment of mitral annular dynamics in consecutive patients with significant mitral valve disease. JACC Cardiovasc Interv, 2021, 14(20): 2215-2227.
38.	Yoon SH, Bleiziffer S, Latib A, et al. Predictors of left ventricular outflow tract obstruction after transcatheter mitral valve replacement. JACC Cardiovasc Interv, 2019, 12(2): 182-193.

1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
2. Davidson LJ, Davidson CJ. Transcatheter treatment of valvular heart disease: a review. JAMA, 2021, 325(24): 2480-2494.
3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e35-e71.
4. Muller DWM, Farivar RS, Jansz P, et al. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol, 2017, 69(4): 381-391.
5. Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
6. Meredith I, Bapat V, Morriss J, et al. Intrepid transcatheter mitral valve replacement system: technical and product description. EuroIntervention, 2016, 12(Y): Y78-Y80.
7. Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
8. Cheung A, Webb J, Verheye S, et al. Short-term results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol, 2014, 64(17): 1814-1819.
9. Barbanti M, Piazza N, Mangiafico S, et al. Transcatheter mitral valve implantation using the HighLife system. JACC Cardiovasc Interv, 2017, 10(16): 1662-1670.
10. Maisano F, Benetis R, Rumbinaite E, et al. 2-year follow-up after transseptal transcatheter mitral valve replacement with the cardiovalve. JACC Cardiovasc Interv, 2020, 13(17): e163-e164.
11. Alperi A, Del Val D, Ferreira-Neto AN, et al. Device profile of the AltaValve system for transcatheter mitral valve replacement: overview of its safety and efficacy. Expert Rev Med Devices, 2020, 17(7): 627-636.
12. Nunes Ferreira-Neto A, Dagenais F, Bernier M, et al. Transcatheter mitral valve replacement with a new supra-annular valve: first-in-human experience with the AltaValve system. JACC Cardiovasc Interv, 2019, 12(2): 208-209.
13. Goel SS, Zuck V, Christy J, et al. Transcatheter mitral valve therapy with novel Supra-Annular AltaValve: first experience in the United States. JACC Case Rep, 2019, 1(5): 761-764.
14. Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol, 2014, 64(21): 2235-2243.
15. Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. J Am Coll Cardiol, 2019, 73(11): 1239-1246.
16. Whisenant B. TCT 8: Updated 30-day outcomes for the U. S. early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. (2019-09-28)[2022-09-08]. https://www.tctmd.com/slide/tct-8-updated-30-day-outcomes-us-early-feasibility-study-sapien-m3-transcatheter-mitral-valve.
17. Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv, 2020, 13(20): 2418-2426.
18. Modine T, Vahl TP, Khalique OK, et al. First-in-human implant of the cephea transseptal mitral valve replacement system. Circ Cardiovasc Interv, 2019, 12(9): e008003.
19. Iung B, Delgado V, Lazure P, et al. Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. Eur Heart J, 2018, 39(15): 1295-1303.
20. Gammie JS, Chikwe J, Badhwar V, et al. Isolated mitral valve surgery: the Society of Thoracic Surgeons Adult Cardiac Surgery Database analysis. Ann Thorac Surg, 2018, 106(3): 716-727.
21. Urena M, Vahanian A, Brochet E, et al. Current indications for transcatheter mitral valve replacement using transcatheter aortic valves: valve-in-valve, valve-in-ring, and valve-in-mitral annulus calcification. Circulation, 2021, 143(2): 178-196.
22. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
23. Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an 8-year single-center experience. JACC Cardiovasc Interv, 2015, 8(13): 1735-1744.
24. D’Onofrio A, Tarja E, Besola L, et al. Early and midterm clinical and hemodynamic outcomes of transcatheter valve-in-valve implantation: results from a multicenter experience. Ann Thorac Surg, 2016, 102(6): 1966-1973.
25. Eleid MF, Whisenant BK, Cabalka AK, et al. Early outcomes of percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc Interv, 2017, 10(19): 1932-1942.
26. Murzi M, Berti S, Gasbarri T, et al. Transapical transcatheter mitral valve-in-valve implantation versus minimally invasive surgery for failed mitral bioprostheses. Interact Cardiovasc Thorac Surg, 2017, 25(1): 57-61.
27. Kamioka N, Babaliaros V, Morse MA, et al. Comparison of clinical and echocardiographic outcomes after surgical redo mitral valve replacement and transcatheter mitral valve-in-valve therapy. JACC Cardiovasc Interv, 2018, 11(12): 1131-1138.
28. Urena M, Brochet E, Lecomte M, et al. Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience. Eur Heart J, 2018, 39(28): 2679-2689.
29. Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J, 2019, 40(5): 441-451.
30. da Costa LPN, Palma JH, Barbosa Ribeiro H, et al. Transcatheter mitral valve-in-valve implantation: reports of the first 50 cases from a Latin American Centre. Interact Cardiovasc Thorac Surg, 2020, 30(2): 229-235.
31. Guerrero M, Vemulapalli S, Xiang Q, et al. Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the united states: data from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv, 2020, 13(3): e008425.
32. Guerrero M, Urena M, Himbert D, et al. 1-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Am Coll Cardiol, 2018, 71(17): 1841-1853.
33. Praz F, Khalique OK, Lee R, et al. Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification. J Thorac Cardiovasc Surg, 2018, 156(1): 132-142.
34. Alperi A, Granada JF, Bernier M, et al. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol, 2021, 77(24): 3058-3078.
35. Gössl M, Thourani V, Babaliaros V, et al. Early outcomes of transcatheter mitral valve replacement with the Tendyne system in severe mitral annular calcification. EuroIntervention, 2022, 17(18): 1523-1531.
36. Hensey M, Brown RA, Lal S, et al. Transcatheter mitral valve replacement: an update on current techniques, technologies, and future directions. JACC Cardiovasc Interv, 2021, 14(5): 489-500.
37. Nakashima M, Williams M, He Y, et al. Multiphase assessment of mitral annular dynamics in consecutive patients with significant mitral valve disease. JACC Cardiovasc Interv, 2021, 14(20): 2215-2227.
38. Yoon SH, Bleiziffer S, Latib A, et al. Predictors of left ventricular outflow tract obstruction after transcatheter mitral valve replacement. JACC Cardiovasc Interv, 2019, 12(2): 182-193.

Next Article
Complications and management of transcatheter edge-to-edge mitral valve repair

West China Medical Journal

Current status of transcatheter mitral valve replacement

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content